Genofocus Stock Earnings Per Share
187420 Stock | 4,175 20.00 0.48% |
GenoFocus fundamentals help investors to digest information that contributes to GenoFocus' financial success or failures. It also enables traders to predict the movement of GenoFocus Stock. The fundamental analysis module provides a way to measure GenoFocus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GenoFocus stock.
GenoFocus |
GenoFocus Company Earnings Per Share Analysis
GenoFocus' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Competition |
According to the company disclosure, GenoFocus has an Earnings Per Share of 0.0 times. This indicator is about the same for the Chemicals average (which is currently at 0.0) sector and about the same as Materials (which currently averages 0.0) industry. This indicator is about the same for all Republic of Korea stocks average (which is currently at 0.0).
Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
All Next | Launch Module |
GenoFocus Fundamentals
Return On Equity | -24.42 | |||
Return On Asset | -0.0291 | |||
Profit Margin | (0.68) % | |||
Operating Margin | (0.25) % | |||
Current Valuation | 231.24 B | |||
Shares Outstanding | 21.54 M | |||
Shares Owned By Insiders | 34.31 % | |||
Shares Owned By Institutions | 0.09 % | |||
Price To Sales | 9.72 X | |||
Revenue | 25.87 B | |||
Gross Profit | 6.06 B | |||
EBITDA | (2.54 B) | |||
Net Income | (8.53 B) | |||
Cash And Equivalents | 25.11 B | |||
Total Debt | 26.94 B | |||
Cash Flow From Operations | (2.39 B) | |||
Number Of Employees | 67 | |||
Beta | 0.8 | |||
Market Capitalization | 132.88 B | |||
Total Asset | 118.52 B | |||
Z Score | 2.4 | |||
Net Asset | 118.52 B |
About GenoFocus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GenoFocus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GenoFocus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GenoFocus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with GenoFocus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GenoFocus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GenoFocus will appreciate offsetting losses from the drop in the long position's value.Moving against GenoFocus Stock
0.67 | 004020 | Hyundai Steel | PairCorr |
0.66 | 051910 | LG Chemicals | PairCorr |
0.62 | 009830 | Hanwha Solutions | PairCorr |
0.61 | 005490 | POSCO Holdings | PairCorr |
0.61 | 001230 | Dongkuk Steel Mill | PairCorr |
The ability to find closely correlated positions to GenoFocus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GenoFocus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GenoFocus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GenoFocus to buy it.
The correlation of GenoFocus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GenoFocus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GenoFocus moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GenoFocus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in GenoFocus Stock
GenoFocus financial ratios help investors to determine whether GenoFocus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GenoFocus with respect to the benefits of owning GenoFocus security.